Research Paper Volume 14, Issue 8 pp 3365—3386

Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties


Figure 3. Effects of the Ras/MEK, PI3K/mTOR and TP53 inhibitors on the growth of MIA-PaCa-2 + WT-TP53 and MIA-PaCa-2 + pLXSN cells. The effects of the ARS-1620 mutant KRas inhibitor (A), the PD0325901 MEK1 inhibitor (B), the LY294002 PI3K inhibitor (C) and the TP53 inhibitor pifithrin-μ (D) on MIA-PaCa-2 + pLXSN cells (solid red squared) and MIA-PaCa-2 + WT-TP53 cells (solid blue circles) were examined by MTT analysis. The MIA-PaCa-2 + WT-TP53, and MIA-PaCa-2 + pLXSN cells in each panel were all examined at the same time period. These experiments were repeated and similar results were obtained. Statistical analyses were performed by the Student T test on the means and standard deviations of various treatment groups. ***P < 0.0001.